No combination trials located
No published clinical study of this four peptide blend was identified on PubMed. Evidence comes from each component studied on its own. Reported in the cited paper.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →

KLOW is a four peptide blend adding KPV, a melanocortin derived tripeptide with anti-inflammatory activity, to the three peptides in GLOW. It is used in regenerative and healing protocols, and the combination itself has no published clinical trial.
Supplier listings
Form
Show prices as
Size
83 listings · KLOW
In stock80mgseen 2w ago
In stock80 mg · 10 vialsseen 5w ago
In stock80mgseen 7w ago
In stock80mgseen 2w ago
In stock80mgseen 8w ago
In stock80mgseen 5w ago
In stock80mgseen 4d ago
In stock80mgseen 2w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 8w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 8w ago
In stock80mgseen 3w ago
In stock80mgseen 5w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 3w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 4w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 8w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 8w ago
In stock80mgseen 7w ago
In stock80mgseen 7w ago
In stock80mgseen 4w ago
In stock80mgseen 7w ago
In stock80 mg · 2 vialsseen 4w ago
In stock80mgseen 8w ago
In stock80mgseen 7w ago
In stock80 mg · 10 vialsseen 7w ago
In stock80 mg · 10 vialsseen 7w ago
Overview
KLOW is a four peptide blend adding KPV, a melanocortin derived tripeptide with anti-inflammatory activity, to the three peptides in GLOW. It is used in regenerative and healing protocols, and the combination itself has no published clinical trial.
What the research reports
Outcomes described across the published literature and ongoing study. Read each as research context rather than a promised personal result.
Added inflammatory control
KPV contributes anti-inflammatory activity through a route largely independent of the melanocortin receptors, complementing the three repair peptides in the stack.
Four pathway repair coverage
Brings together collagen signalling, angiogenesis, actin regulation and inflammatory suppression within a single research protocol. Reported in research settings.
Gut inflammation focus work
KPV has published animal work in colitis models, which adds a gut dimension alongside the BPC-157 component. Noted across the published research record.
Skin and wound application
The GHK-Cu and KPV components both feature in skin research, broadening the blend beyond musculoskeletal recovery. Noted across the published research record.
Component level study support
Each peptide carries its own preclinical record, so the blend inherits the evidence of its parts rather than adding its own. Reported in research settings.
Clinical evidence
The published record, labeled by strength so you can see what is settled and what is still emerging.
No published clinical study of this four peptide blend was identified on PubMed. Evidence comes from each component studied on its own. Reported in the cited paper.
SourceAn animal study reported that the melanocortin derived tripeptide KPV produced significant anti-inflammatory effects across two murine models of colitis. Reported in the cited paper.
SourceA study reported that KPV is taken into cells through the PepT1 transporter and reduced intestinal inflammation in chemically induced colitis models. Reported in the cited paper.
SourceInteractions
Questions